PHAXIAM Therapeutics S.A. Cash Flow Conversion Efficiency

Latest as of June 2024: -0.540x

PHAXIAM Therapeutics S.A. cash flow conversion efficiency. Based on the latest financial reports, PHAXIAM Therapeutics S.A. (PHXM) has a cash flow conversion efficiency ratio of -0.540x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-8.34 Million ≈ $-9.75 Million USD) by net assets (€15.45 Million ≈ $18.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of PHAXIAM Therapeutics S.A. (2012–2023)

Cash flow conversion efficiency of PHAXIAM Therapeutics S.A. from 2012 to 2023. This chart illustrates how PHAXIAM Therapeutics S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View PHAXIAM Therapeutics S.A. stock quote for real-time trading data and today's change.

PHAXIAM Therapeutics S.A. Cash Flow Conversion Ratio Explained

PHAXIAM Therapeutics S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

PHAXIAM Therapeutics S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PHAXIAM Therapeutics S.A. ranked by their cash flow conversion efficiency. Also see PHXM market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Lucky Minerals Inc V:LKY	0.000x
Avation PLC LSE:AVAP	-0.005x
Boardwalktech Software Corp V:BWLK	-0.072x
Audioboom Group plc LSE:BOOM	0.076x
BioNeutra Global Corp V:BGA	-0.004x
Antarctica Limited NSE:ANTGRAPHIC	0.098x
Alligator Bioscience AB ST:ATORX	-4.204x
Anpario Plc LSE:ANP	0.112x

Annual Cash Flow Conversion Efficiency for PHAXIAM Therapeutics S.A. (2012–2023)

The table below shows the annual cash flow conversion efficiency of PHAXIAM Therapeutics S.A. from 2012 to 2023. Review free cash flow generation of PHAXIAM Therapeutics S.A. to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2023-12-31	€25.61 Million ≈ $29.94 Million	€-24.43 Million ≈ $-28.56 Million	-0.954x	+29.97%
2022-12-31	€23.49 Million ≈ $27.46 Million	€-31.99 Million ≈ $-37.40 Million	-1.362x	+45.55%
2021-12-31	€22.84 Million ≈ $26.71 Million	€-57.14 Million ≈ $-66.81 Million	-2.501x	-27.55%
2020-12-31	€26.54 Million ≈ $31.03 Million	€-52.05 Million ≈ $-60.85 Million	-1.961x	-285.69%
2019-12-31	€85.56 Million ≈ $100.03 Million	€-43.51 Million ≈ $-50.86 Million	-0.508x	-88.53%
2018-12-31	€145.60 Million ≈ $170.22 Million	€-39.27 Million ≈ $-45.91 Million	-0.270x	-98.08%
2017-12-31	€181.42 Million ≈ $212.10 Million	€-24.70 Million ≈ $-28.88 Million	-0.136x	+72.50%
2016-12-31	€35.64 Million ≈ $41.66 Million	€-17.64 Million ≈ $-20.63 Million	-0.495x	-60.07%
2015-12-31	€47.13 Million ≈ $55.10 Million	€-14.58 Million ≈ $-17.04 Million	-0.309x	-53.08%
2014-12-31	€35.82 Million ≈ $41.88 Million	€-7.24 Million ≈ $-8.46 Million	-0.202x	+57.59%
2013-12-31	€13.59 Million ≈ $15.88 Million	€-6.47 Million ≈ $-7.57 Million	-0.476x	-208.76%
2012-12-31	€-4.03 Million ≈ $-4.71 Million	€621.40K ≈ $726.48K	-0.154x	--

About PHAXIAM Therapeutics S.A.

PA:PHXM France Biotechnology

Market Cap

$1.18 Million

€1.01 Million EUR

Market Cap Rank

#30662 Global

#571 in France

Share Price

€0.10

Change (1 day)

+0.00%

52-Week Range

€0.10 - €0.10

All Time High

€283.83